Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free AEON Stock Alerts

AEON Biopharma (AEON) Competitors

AEON Biopharma logo
$0.25 -0.01 (-3.58%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$0.25 0.00 (-1.87%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AEON vs. ATNM, PLRZ, BTAI, TAOX, and TVRD

Should you buy AEON Biopharma stock or one of its competitors? MarketBeat compares AEON Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AEON Biopharma include Actinium Pharmaceuticals (ATNM), Polyrizon (PLRZ), BioXcel Therapeutics (BTAI), Synaptogenix (TAOX), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry.

How does AEON Biopharma compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

AEON Biopharma has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium Pharmaceuticals$90K299.81-$48.82M-$0.75N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 481.40%. Given Actinium Pharmaceuticals' higher probable upside, equities analysts plainly believe Actinium Pharmaceuticals is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Actinium Pharmaceuticals had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Actinium Pharmaceuticals and 0 mentions for AEON Biopharma. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat AEON Biopharma's score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Actinium Pharmaceuticals Positive
AEON Biopharma Neutral

AEON Biopharma's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
AEON Biopharma N/A N/A -994.63%

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Actinium Pharmaceuticals has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Summary

Actinium Pharmaceuticals beats AEON Biopharma on 7 of the 13 factors compared between the two stocks.

How does AEON Biopharma compare to Polyrizon?

AEON Biopharma (NASDAQ:AEON) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
PolyrizonN/AN/A-$3.34MN/AN/A

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Polyrizon N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Polyrizon
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

AEON Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.59, indicating that its share price is 259% less volatile than the broader market.

22.8% of AEON Biopharma shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Polyrizon had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Polyrizon and 0 mentions for AEON Biopharma. Polyrizon's average media sentiment score of 1.32 beat AEON Biopharma's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company Overall Sentiment
AEON Biopharma Neutral
Polyrizon Positive

Summary

AEON Biopharma beats Polyrizon on 6 of the 10 factors compared between the two stocks.

How does AEON Biopharma compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AEON Biopharma has lower revenue, but higher earnings than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioXcel Therapeutics$680K38.48-$69.90M-$5.75N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

BioXcel Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 1,197.94%. Given BioXcel Therapeutics' higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioXcel Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, BioXcel Therapeutics had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for BioXcel Therapeutics and 0 mentions for AEON Biopharma. BioXcel Therapeutics' average media sentiment score of 1.87 beat AEON Biopharma's score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
BioXcel Therapeutics Very Positive
AEON Biopharma Neutral

BioXcel Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

AEON Biopharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company Net Margins Return on Equity Return on Assets
BioXcel Therapeutics-11,078.53% N/A -201.53%
AEON Biopharma N/A N/A -994.63%

Summary

AEON Biopharma beats BioXcel Therapeutics on 8 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and AEON Biopharma (NASDAQ:AEON) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Synaptogenix had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for AEON Biopharma. Synaptogenix's average media sentiment score of 1.87 beat AEON Biopharma's score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media.

Company Overall Sentiment
Synaptogenix Very Positive
AEON Biopharma Neutral

Synaptogenix has higher revenue and earnings than AEON Biopharma. Synaptogenix is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synaptogenix$687.84K35.74-$28.74M-$13.28N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

Synaptogenix has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

AEON Biopharma's return on equity of 0.00% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SynaptogenixN/A -163.40% -133.47%
AEON Biopharma N/A N/A -994.63%

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

AEON Biopharma beats Synaptogenix on 8 of the 14 factors compared between the two stocks.

How does AEON Biopharma compare to Tvardi Therapeutics?

AEON Biopharma (NASDAQ:AEON) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

AEON Biopharma's return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Tvardi Therapeutics N/A -64.17%-43.90%

Tvardi Therapeutics has a consensus price target of $19.67, indicating a potential upside of 683.53%. Given Tvardi Therapeutics' higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Tvardi Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
Tvardi TherapeuticsN/AN/A-$18.21M-$3.10N/A

In the previous week, Tvardi Therapeutics had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 0 mentions for AEON Biopharma. Tvardi Therapeutics' average media sentiment score of 0.99 beat AEON Biopharma's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
AEON Biopharma Neutral
Tvardi Therapeutics Positive

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AEON Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Summary

Tvardi Therapeutics beats AEON Biopharma on 8 of the 13 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AEON vs. The Competition

Export
MetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.34M$975.11M$6.86B$12.25B
Dividend YieldN/A4.84%2.67%9.79%
P/E Ratio1.391.5327.1423.64
Price / SalesN/A105.75517.0189.03
Price / CashN/A20.0650.5459.64
Price / Book-0.068.4710.286.07
Net Income-$36.63M-$2.70M$3.60B$331.99M
7 Day Performance-14.99%-2.29%-1.27%-0.63%
1 Month Performance-63.67%-3.97%-0.37%-2.00%
1 Year Performance-68.26%27.39%18.30%13.62%

AEON Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEON
AEON Biopharma
0.8211 of 5 stars		$0.25
-3.6%		N/A-69.1%$6.34MN/A1.395
ATNM
Actinium Pharmaceuticals
2.3619 of 5 stars		$0.90
+1.9%		$5.00
+455.6%		-52.7%$28.24M$90KN/A30
PLRZ
Polyrizon
0.4575 of 5 stars		$13.49
+1.7%		N/A+76.0%$28.06MN/AN/AN/A
BTAI
BioXcel Therapeutics
2.7689 of 5 stars		$0.90
+1.7%		$11.00
+1,125.5%		-51.0%$27.72M$640KN/A90
TAOX
Synaptogenix
0.7063 of 5 stars		$3.66
+2.2%		N/AN/A$27.34M$300KN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel